The Sequence Listing associated with this application is filed in electronic format via EFS-Web and is hereby incorporated by reference into the specification in its entirety.
All publications cited in this application are herein incorporated by reference.
Most commercial or industrial yeast are of the species Saccharomyces cerevisiae and are capable of growth on non-fermentable carbon sources and thus contain an intact mitochondrial genome (termed petite positive). Petite positive yeast like S. cerevisiae are able to grow on a fermentable carbon source in the absence of mitochondrial DNA (mtDNA).
The foregoing examples of related art and limitations related therewith are intended to be illustrative and not exclusive, and they do not imply any limitations on the inventions described herein. Other limitations of the related art will become apparent to those skilled in the art upon a reading of the specification and a study of the drawings.
The following embodiments and aspects thereof are described and illustrated in conjunction with systems, tools and methods, which are meant to be exemplary and illustrative, not limiting in scope.
An embodiment of the present invention may comprise a method for enhanced fermentation of plant material through the genetic modification of non-respiring yeast comprising removing a mitochondrial gene from mitochondrial DNA of the non-respiring yeast, while leaving the rest of the mitochondrial genome of the non-respiring yeast intact, wherein the removed mitochondrial gene is a COX1, COX2, COX3, or COB gene and producing a non-respiring yeast where the non-respiring yeast is capable of fermenting plant material.
An embodiment of the present invention may comprise a transgenic non-respiring yeast having a mitochondrial gene removed from the mitochondrial DNA of the yeast while leaving the rest of the yeast mitochondrial genome intact, wherein the removed mitochondrial gene is a COX1, COX2, COX3, or COB gene.
An embodiment of the present invention may comprise a method for enhanced fermentation of plant material through the genetic modification of non-respiring yeast comprising: introducing a dominant mitochondrial ATP synthase gene mutation into the yeast and removing a mitochondrial gene from mitochondrial DNA of the non-respiring yeast while leaving the rest of the mitochondrial genome of the non-respiring yeast intact, wherein the removed mitochondrial gene is COX1, COX2, COX3, or COB gene.
An embodiment of the present invention may comprise a transgenic non-respiring yeast comprising a dominant mitochondrial ATP synthase gene mutation and a mitochondrial genome lacking the COX1, COX2, COX3, or COB gene.
An embodiment of the present invention may comprise a method for enhanced fermentation of plant material through the genetic modification of non-respiring yeast comprising: introducing a dominant mitochondrial ATP synthase gene mutation into the yeast.
An embodiment of the present invention may comprise a DNA construct for enhanced yeast fermentation of plant material through the genetic modification of non-respiring yeast wherein the construct comprises: a dominant mitochondrial ATP synthase gene mutation and a selectable marker, wherein the dominant mitochondrial ATP synthase gene mutation is operably linked to the selectable marker.
An embodiment of the present invention may comprise a transgenic non-respiring yeast having a DNA construct stably integrated into the transgenic non-respiring yeast under conditions suitable for expression of the DNA construct in transgenic non-respiring yeast, wherein the DNA construct comprises a dominant mitochondrial ATP synthase gene mutation and a selectable marker.
An embodiment of the present invention may comprise a method for enhanced fermentation of plant material through the genetic modification of non-respiring yeast comprising deleting a CAT5 nuclear gene of the non-respiring yeast but leaving the mitochondrial genome of the non-respiring yeast intact.
An embodiment of the present invention may comprise a transgenic non-respiring yeast having a CAT5 nuclear gene of the non-respiring yeast deleted from the yeast mitochondrial genome but leaving the mitochondrial genome of the non-respiring yeast intact.
An embodiment of the present invention may comprise a method for enhanced fermentation of plant material through the genetic modification of non-respiring yeast comprising: introducing a dominant mitochondrial ATP synthase gene mutation into the yeast and destroying a CAT5 nuclear gene of the yeast.
An embodiment of the present invention may comprise a transgenic non-respiring yeast comprising a dominant mitochondrial ATP synthase gene mutation and lacking a CAT5 nuclear gene.
In addition to the example, aspects and embodiments described above, further aspects and embodiments will become apparent by reference to the drawings and by study of the following descriptions, any one or all of which are within the embodiments of the invention. The summary above is a list of example implementations, not a limiting statement of the scope of the embodiments of the invention.
The accompanying figures, which are incorporated herein and form a part of the specification, illustrate some, but not the only or exclusive, example embodiments and/or features. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than limiting.
a is a DNA construct with the dominant ATP1-111 allele operably linked to a dominant selectable marker.
b is a second DNA construct with the dominant ATP1-111 allele operably linked to a dominant selectable marker.
a,
a and
a and
SEQ ID NO:1 discloses the ATP1-111 protein sequence with an amino acid change of Val to Phe at location 111.
SEQ ID NO:2 discloses the ATP1-111 nucleic acid sequence of ORF with G to T change at location 331.
SEQ ID NO:3 discloses the DNA sequence immediately 5′ to the ATP1 open reading frame.
SEQ ID NO:4 discloses the DNA sequence immediately 3′ to the ATP1 open reading frame.
SEQ ID NO:5 discloses the repetitive DNA sequence element used in the construction of a construct containing a dominant genetic marker such as KAN-MX.
SEQ ID NO:6 discloses the forward PCR primer for ATP1 sequencing.
SEQ ID NO:7 discloses the reverse PCR primer for ATP1 sequencing.
SEQ ID NO:8 discloses the forward PCR primer for cloning ATP1 alleles.
SEQ ID NO:9 discloses the reverse PCR primer for cloning ATP1 alleles.
Embodiments of the present disclosure include methods for enhancing yeast fermentation of plant material through the genetic modification of non-respiring yeast, where the term “yeast” includes but is not limited to Saccharomyces cerevisiae. The methods for enhancing fermentation of yeast described in the present disclosure proceed through the alteration of yeast nuclear or mitochondrial genes required for growth on non-fermentable carbon sources (such as a disrupted copy of the CAT5 gene, dominant mutations in mitochondrial ATP synthase genes, or a mitochondrial genome lacking the COX1, COX2, COX3, or COB gene). The transgenic yeast of the present disclosure having a nonfunctional or absent mitochondrial DNA express enhanced fermentation and improved growth because the yeast are unable to invoke respiratory pathways, consequently preventing the metabolism or consumption of desirable fermentation intermediates or products (such as pyruvate and ethanol, respectively) and preventing significant growth defects in the transgenic yeast that preclude their use for commercial purposes, thereby increasing yeast ethanol production and yields (approximately 25% or more).
One or more embodiments of the present invention include methods for increasing the ethanol production of non-respiring yeast by providing methods for enhancing the fermentation of plant material by non-respiring yeast. One or more of these methods may include stably introducing a construct into a transgenic non-respiring yeast comprising a dominant mutation in a gene or genes encoding the mitochondrial ATP synthase such as the dominant ATP1-111 mutation of SEQ ID NO:1 or SEQ ID NO: 2. Additional embodiments may comprise a transgenic non-respiring yeast having the DNA construct for the expression of a dominant mitochondrial ATP synthase gene mutation stably integrated into the yeast's genome under conditions suitable for the expression of a dominant mitochondrial ATP synthase gene mutation. Further embodiments for increasing ethanol production may include integration of a dominant mitochondrial ATP synthase gene mutation into the yeast's genome under conditions suitable for the expression of a dominant mitochondrial ATP synthase gene mutation, where, as will be discussed in more detail later, the transgenic yeast with the dominant mitochondrial ATP synthase gene mutation also has a mitochondrial genome lacking the COX1, COX2, COX3, or COB gene or a disrupted a copy of the CAT5 gene from the transgenic non-respiring yeast's nuclear genome. As used herein, the term “expression” includes the process by which information from a gene is used in the synthesis of a functional gene product.
One or more embodiments of the present disclosure for increasing yeast ethanol production include a method comprising removing the intact mitochondrial genome from a non-respiring yeast containing the COX1, COX2, COX3, or COB gene and then introducing a new mitochondrial genome back into the non-respiring yeast where the new mitochondrial genome lack the COX1, COX2, COX3, or COB gene. Additional embodiments may comprise a transgenic non-respiring yeast produced from this method where the yeast mitochondrial genome lacks the COX1, COX2, COX3, or COB gene.
Another embodiment of the present invention includes another method for enhancing non-respiring yeast fermentation of plant material comprising disrupting a copy of the CAT5 gene from the transgenic non-respiring yeast's nuclear genome. An embodiment may further comprise a transgenic non-respiring yeast, having a disrupted copy of the CAT5 gene.
Mitochondria contain a small genome (mtDNA) encoding a subset of mitochondrially localized proteins. The mitochondrial genome is 75-85 kb in size in Saccharomyces cerevisiae (yeast) and encodes the mitochondrial ribosomal protein Var1, tRNAs, rRNAs, four cytochrome oxidase subunits that are part of the electron transport chain (COX1, COX2, COX3, and COB) and three subunits of the proton-translocating F0 portion of the F1F0-ATPase (Atp6, Atp8, and Atp9) (see Smith et al, Genetics 179: 1285-1299 (2008)). Yeast strains with intact, fully-functional mtDNA (ρ+ strains) can be converted into strains without mtDNA (ρ° strains) or with dysfunctional mtDNA (ρ− strains) by inclusion of ethidium bromide (EtBr) in the growth media. Because S. cerevisiae mtDNA encodes subunits of electron transport complexes and the Fo component of ATP synthase, no electron transport or oxidative phosphorylation is possible in ρ° or ρ− strains. Yeast is considered a petite-positive organism because it is able to grow without mtDNA (ρ°) or with a mitochondrial genome severely compromised by extensive deletions (ρ−). Because four subunits of the electron transport chain and three subunits of the F0 portion of the F1F0-ATPase are encoded by mtDNA, yeast lacking a mitochondrial genome must maintain membrane potential (ΔψM) by exchange of ATP4− for ADP3− through the ADP/ATP carrier. ADP3− is provided by the hydrolysis of ATP4−, catalyzed by the remaining F1 portion of the ATPase (F1− ATPase).
As shown in
In
In
Saccharomyces cerevisiae is routinely used in ethanolic fermentations that produce biofuels. This yeast is capable of fermentation of hexoses, such as glucose, to ethanol in the absence or presence of oxygen. Pyruvate is the theoretical endpoint of glycolysis, but continued fermentative metabolism requires the reduction of pyruvate to lactate or the reduction of the pyruvate derivative acetaldehyde to ethanol, this latter process being the major fermentative outcome in yeast. In the presence of oxygen, pyruvate can alternatively be subjected to complete oxidation using enzymes of the tricarboxylic acid (TCA) cycle, with electrons stripped from pyruvate being ultimately donated to oxygen. Consequently, one outcome of glucose metabolism in yeast (and many organisms) is the coupling of glycolysis (production of pyruvate) to the oxidative degradation of pyruvate by the TCA cycle with the ultimate transfer of electrons gathered during these processes to oxygen (cellular respiration), resulting in the generation of ATP. However, if glucose is plentiful S. cerevisiae will metabolize glucose largely (but not exclusively) by fermentation as it provides the most rapid way to gain sufficient energy for biosynthesis and cell growth. As glucose becomes limiting, cellular respiration is engaged to extract energy from alternative carbon sources, principally the ethanol that was the end-product during the fermentative phase of growth.
Oxidation of pyruvate in yeast requires a functional mitochondrial electron transport chain. The passage of electrons through the electron transport chain is coupled to the establishment of a proton gradient across the inner mitochondrial membrane. This proton gradient is then used for a number of important mitochondrial processes. The most obvious use of the proton gradient is to power the synthesis of ATP via the mitochondrial ATP synthase (also known as the F1Fo-ATPase). The transport of metabolites and proteins across the inner mitochondrial membrane is also dependent upon the membrane potential established by the proton gradient, and is in fact essential for cell viability. It is possible to completely inhibit mitochondrial ATP synthase and generate ATP by glycolysis and cells will remain viable. However, if the electrical gradient across the mitochondrial membrane is dissipated, cells will die because essential biochemical pathways housed in the mitochondrial matrix are no longer functional (see Pedersen, P. L., J Bioenerg Biomembr, 31(4): p. 291-304 (1999)). Importantly, if the inner mitochondrial membrane potential is too low, numerous process throughout the cell become compromised and in yeast the growth rate is significantly reduced (Veatch, J. R., et al., Cell, 137(7): p. 1247-58 (2009) and Francis, B. R., K. H. White, and P. E. Thorsness, J Bioenerg Biomembr, 39(2): p. 127-44, (2007)).
Non-respiring yeast (ρ° or ρ−) lack mitochondrial DNA and have been shown to have enhanced fermentative outcomes with respect to the yield of ethanol production (Toksoy et al. Applied and environmental microbiology, 71(10): p. 6443-5 (2005) and Dikicioglu, D., et al., Applied and environmental microbiology, 74(18): p. 5809-16 (2008)), presumably because available pyruvate is not lost to oxidation. Despite this, respiring yeast (ρ+) have been preferred for fermentation because they grow more robustly than ρ° yeast. Table 1 below shows a list of isolated mutations in mitochondrial ATP synthase genes that may be used for the dominant mitochondrial ATP synthase gene mutation of the present disclosure and discussed further in the construct of
The dominant mitochondrial ATP synthase gene mutations listed in Table 1 improve the growth of non-respiring yeast in laboratory strains also lead to robust growth of ethanologenic strains currently used in commercial fermentative processes. Introduction of the ATP1, ATP2 or ATP3 mutations of Table 1 into ethanologenic non-respiring yeast strains that have been optimized for tolerance to environmental inhibitors and modified to ferment a diversity of saccharides will significantly enhance fermentation and ethanol production. These dominant mutations encode the alpha, beta and gamma subunits of the F1 subunit of mitochondrial ATP synthase. The molecular basis by which the mutation optimizes the growth of ρ° yeast is via an enhancement of mitochondrial membrane potential due to increased hydrolysis of ATP and the consequent enhanced flux of ATP/ADP exchange across the inner mitochondrial membrane. The mutation optimizes ρ° yeast growth and thus increases the efficiency of fermentation in industrial strains of yeast by allowing them to grow robustly as ρ° derivatives. Additionally, the use of the methods described in
The advantages of using vigorous non-respiring yeast (ρ° or ρ−) in fermentations includes allowing for less rigorous fermentation conditions, such as an anaerobic environment not being required for the yeast to efficiently ferment and not undertake respiratory metabolism, as well as producing a greater yield of ethanol per unit of glucose metabolized (no oxidative metabolism of ethanol as glucose becomes limiting). Hence, the introduction of the ATP1-111 mutation (SEQ ID NO:1 or SEQ ID NO:2) or other dominant mutant alleles of ATP1, ATP2, or ATP3 that enhances the fermentative growth of non-respiring yeast into ethanologenic yeast strains that can be used in commercial applications will be a significant technical advance. Importantly, as will be discussed further in the Examples listed below, these dominant mutations grow as robustly as the parental yeast strain bearing intact mitochondrial DNA and produce as much as 25% more ethanol than the ρ+ strain when given the same amount of glucose with doubling times equal to the ρ+ strain.
As shown in
The ATP1-111 mutation is a suppressor of the slow-growth non-respiring yeast lacking mitochondrial DNA due to the substitution of phenylalanine for valine at position 111 of the alpha-subunit of mitochondrial ATP synthase (Atp1p in yeast). The suppressing activity of ATP1-111 requires intact beta (Atp2p) and gamma (Atp3p) subunits of mitochondrial ATP synthase, but not the stator stalk subunits b (Atp4p) and OSCP (Atp1p). ATP1-111 and other similarly suppressing mutations in ATP1 and ATP3 increase the growth rate of wild-type strains lacking mitochondrial DNA. These suppressing mutations decrease the growth rate of yeast containing an intact mitochondrial chromosome on media requiring oxidative phosphorylation, but not when grown on fermentable media.
As shown in
As used herein “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
A variety of transformation techniques are available and known to those skilled in the art for introduction of constructs into a yeast. As described earlier, all DNA manipulations were performed using standard techniques (Sambrook et al., (1989)). To confirm the presence of the transgenes or the absence of genes in yeast, including the COX1, COX2, COX3, or COB gene or CAT5 gene, a polymerase chain reaction (PCR) amplification or Southern blot analysis can be performed using methods known to those skilled in the art.
Generally, the DNA that is introduced into an organism is part of a construct, as described in
The products of the genes are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is a functional RNA. The process of gene expression is used by all known life forms, i.e., eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea), and viruses, to generate the macromolecular machinery for life. Several steps in the gene expression process may be modulated, including the transcription, up-regulation, RNA splicing, translation, and post translational modification of a protein.
A promoter is a DNA region, which includes sequences sufficient to cause transcription of an associated (downstream) sequence. The promoter may be regulated, i.e., not constitutively acting to cause transcription of the associated sequence. If inducible, there are sequences present therein which mediate regulation of expression so that the associated sequence is transcribed only when an inducer molecule is present. The promoter may be any DNA sequence that shows transcriptional activity in the chosen yeast cell. The promoter may be inducible or constitutive. It may be naturally-occurring, may be composed of portions of various naturally-occurring promoters, or may be partially or totally synthetic. Guidance for the design of promoters is derived from studies of promoter structure, such as that of Harley and Reynolds, Nucleic Acids Res., 15, 2343-61 (1987). In addition, the location of the promoter relative to the transcription start may be optimized. Many suitable promoters for use in yeast are well known in the art, as are nucleotide sequences, which enhance expression of an associated expressible sequence.
While the lac promoter is an example of a promoter that may be used, a number of promoters may be used herein. Promoters can be selected based on the desired outcome. That is, the nucleic acids can be combined with constitutive, tissue-preferred, or other promoters for expression in the host cell of interest. The promoter may be inducible or constitutive. It may be naturally-occurring, may be composed of portions of various naturally-occurring promoters, or may be partially or totally synthetic. In addition, the location of the promoter relative to the transcription start may be optimized. Many suitable promoters for use in yeast are well known in the art, as are nucleotide sequences, which enhance expression of an associated expressible sequence.
Subunit I (CoxI) of cytochrome c oxidase is a protein subunit of the terminal member of the mitochondrial inner membrane electron transport chain. The gene that encodes this protein is encoded on mitochondrial DNA and is designated COX1.
Cytochrome c oxidase subunit II, abbreviated COX2, is the second subunit of cytochrome c oxidase. Cytochrome c oxidase is an oligomeric enzymatic complex which is a component of the respiratory chain and is involved in the transfer of electrons from cytochrome c to oxygen. In eukaryotes this enzyme complex is located in the mitochondrial inner membrane; in aerobic prokaryotes it is found in the plasma membrane.
Subunit II (Cox2) transfers the electrons from cytochrome c to the catalytic subunit 1. It contains two adjacent transmembrane regions in its N-terminus and the major part of the protein is exposed to the periplasmic or to the mitochondrial intermembrane space, respectively. Cox2 provides the substrate-binding site and contains a copper centre called Cu(A), probably the primary acceptor in cytochrome c oxidase. An exception is the corresponding subunit of the cbb3-type oxidase which lacks the copper A redox-centre.
Subunit III (Coxa) of cytochrome c oxidase, the gene encoding this protein is abbreviated COX3, is the terminal member of the mitochondrial inner membrane electron transport chain. Cytochrome c oxidase is an oligomeric enzymatic complex which is a component of the respiratory chain and is involved in the transfer of electrons from cytochrome c to oxygen. In eukaryotes this enzyme complex is located in the mitochondrial inner membrane; in aerobic prokaryotes it is found in the plasma membrane.
Cytochrome b, abbreviated Cobp, is the mitochondrially encoded subunit of the ubiquinol-cytochrome c reductase complex. This multisubunit protein complex, also known as complex III, is located in the mitochondrial inner membrane. The gene on the mitochondrial chromosome that encodes this protein is named COB.
CAT5 is a ubiquinone biosynthesis gene found in yeast. The deletion of the CAT5 gene decreases respiratory growth by precluding electron transport from contributing to membrane potential in mitochondria, but unlike the loss of mtDNA, the formation of coupled F1 Fo-ATPase is not impaired.
Standard genetic techniques were used to construct and analyze the various strains of the present disclosure (see Sherman et al., 1986). Escherichia coli strain XL-1 Blue (Stratagene) was used for preparation and manipulation of DNA. Plasmids containing E. coli were grown in Luria-Bertani (LB) broth supplemented with 125 μg/ml ampicillin (Sambrook et al., (1989)). Yeast strains were grown in rich glucose medium (YPD) containing 2% glucose, 2% Bacto peptone, 1% yeast extract (Difco), 40 mg/l adenine and 40 mg/l tryptophan; rich ethanol glycerol medium (YPEG) containing 3% ethanol, 3% glycerol, 2% Bacto peptone, 1% yeast extract (Difco), 40 mg/l adenine and 40 mg/l tryptophan; rich raffinose medium (YPR) in which filter sterilized raffinose replaced glucose in the YPD formulation; synthetic glucose medium (SD) containing 2% glucose, 6.7 g/l Yeast Nitrogen Base without amino acids (Difco) supplemented with appropriate nutrients; synthetic ethanol glycerol medium (SEG) containing 3% ethanol, 3% glycerol, 6.7 g/l Yeast Nitrogen Base without amino acids (Difco) supplemented with appropriate nutrients; and sporulation medium (SPO) containing 1% potassium acetate supplemented with the complete set of nutrients. The complete set of nutrients is uracil 40 mg/l, adenine 40 mg/l, tryptophan 40 mg/l, lysine 60 mg/l, leucine 100 mg/l, histidine 20 mg/l, isoleucine 30 mg/l, and valine 150 mg/l. For plates, bacteriological agar (US Biological) was added at 15 g/l. Where indicated, ethidium bromide (EtBr) was added at 25 μg/ml and geneticin at 300 μg/ml, or nourseothricin (Werner Bioagents) was top spread on plates at 25 μg/ml. All yeast media were incubated at 30.0 except SPO, which was incubated at room temperature. LB medium was incubated at 37° C. When ρ° strains were specifically used (
PCR primers for ATP1 sequencing were (SEQ ID NO:6) (forward) (SEQ ID NO:7) (reverse). For cloning, ATP1 alleles were PCR amplified from genomic DNA using Pfu Turbo DNA polymerase (Stratagene). Primers were (SEQ ID NO:8) (forward) and (SEQ ID NO:9) (reverse).
Isolation of mitochondria, immuno-detection of proteins and measurement of F1Fo-ATPase activity Mitochondrial isolation was performed as described by Yaffe, 1991. Cells were grown in 1 liter of YPR to OD600=1.5. Mitochondrial yield was determined using the Coomassie Protein Assay (Pierce). ATPase activities were determined using isolated mitochondria essentially as described (see Tzagoloff, Methods Enzymol 55:351-358, (1979)). Reaction mixtures contained 120 μg of mitochondria and were incubated at 37.0 for 12 minutes.
As used herein plasmid, vector or cassette refers to an extrachromosomal element often carrying genes and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with an appropriate 3′ untranslated sequence into a cell.
While one example of an expression vector is the recombinant vector of
To construct the vector, the upstream DNA sequences of a gene expressed under control of a suitable promoter may be restriction mapped and areas important for the expression of the protein characterized. The exact location of the start codon of the gene is determined and, making use of this information and the restriction map, a vector may be designed for expression of a heterologous protein by removing the region responsible for encoding the gene's protein but leaving the upstream region found to contain the genetic material responsible for control of the gene's expression. A synthetic oligonucleotide is inserted in the location where the protein sequence once was, such that any additional gene could be cloned in using restriction endonuclease sites in the synthetic oligonucleotide (i.e., a multicloning site). Publicly available restriction proteins may be used for the development of the constructs. An unrelated gene (or coding sequence) inserted at this site would then be under the control of an extant start codon and upstream regulatory region that will drive expression of the foreign (i.e., not normally present) protein encoded by this gene. Once the gene for the foreign protein is put into a cloning vector, it can be introduced into the host organism using any of several methods, some of which might be particular to the host organism. Variations on these methods are described in the general literature. Manipulation of conditions to optimize transformation for a particular host is within the skill of the art.
The basic techniques used for transformation and expression in yeast are known in the art. Exemplary methods have been described in a number of texts for standard molecular biological manipulation (see Sambrook et al. (1989)). These methods include, for example, biolistic devices (See, for example, Sanford, Trends In Biotech., 6: 299-302, (1988)); U.S. Pat. No. 4,945,050; use of a laser beam, electroporation, microinjection or any other method capable of introducing DNA into a host cell (e.g., an NVPO).
To confirm the presence of the transgenes in transgenic cells, a polymerase chain reaction (PCR) amplification or Southern blot analysis can be performed using methods known to those skilled in the art. Expression products of the transgenes can be detected in any of a variety of ways, depending upon the nature of the product, and include Western blot and enzyme assay. Once transgenic organisms have been obtained, they may be grown to produce organisms or parts having the desired phenotype.
A selectable marker (SM) such as the KAN-MX gene of the construct of
The transcription termination region of the constructs is a downstream regulatory region including the stop codon and the transcription terminator sequence. Alternative transcription termination regions that may be used may be native with the transcriptional initiation region, may be native with the DNA sequence of interest, or may be derived from another source. The transcription termination region may be naturally occurring, or wholly or partially synthetic.
The practice described herein employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. (See, e.g., Maniatis, et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1982); Sambrook, et al., (1989); Sambrook and Russell, Molecular Cloning, 3rd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2001); Ausubel, et al., Current Protocols in Molecular Biology, John Wiley & Sons (including periodic updates) (1992); Glover, DNA Cloning, IRL Press, Oxford (1985); Russell, Molecular biology of plants: a laboratory course manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1984); Anand, Techniques for the Analysis of Complex Genomes, Academic Press, NY (1992); Guthrie and Fink, Guide to Yeast Genetics and Molecular Biology, Academic Press, NY (1991); Harlow and Lane, Antibodies, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988); Nucleic Acid Hybridization, B. D. Hames & S. J. Higgins eds. (1984); Transcription And Translation, B. D. Hames & S. J. Higgins eds. (1984); Culture Of Animal Cells, R. I. Freshney, A. R. Liss, Inc. (1987); Immobilized Cells And Enzymes, IRL Press (1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology, Academic Press, Inc., NY); Methods In Enzymology, Vols. 154 and 155, Wu, et al., eds.; Immunochemical Methods In Cell And Molecular Biology, Mayer and Walker, eds., Academic Press, London (1987); Handbook Of Experimental Immunology, Volumes I-IV, D. M. Weir and C. C. Blackwell, eds. (1986); Riott, Essential Immunology, 6th Edition, Blackwell Scientific Publications, Oxford (1988); Fire, et al., RNA Interference Technology From Basic Science to Drug Development, Cambridge University Press, Cambridge (2005); Schepers, RNA Interference in Practice, Wiley-VCH (2005); Engelke, RNA Interference (RNAi): The Nuts & Bolts of siRNA Technology, DNA Press (2003); Gott, RNA Interference, Editing, and Modification: Methods and Protocols (Methods in Molecular Biology), Human Press, Totowa, N.J. (2004); and Sohail, Gene Silencing by RNA Interference: Technology and Application, CRC (2004)).
The following examples are provided to illustrate further the various applications and are not intended to limit the invention beyond the limitations set forth in the appended claims.
Table 2 below shows the growth doubling time of related yeast strains, differing from each other on the basis of whether or not they contain mitochondrial DNA and consequently a functional electron transport chain. Column 1 shows the yeast strain name, column 2 shows the relevant yeast genotype and column 3 shows the doubling time of the yeast strain grown in a YPD media. As shown in Table 2, mutations in mitochondrial ATP synthase genes have been provided that enhance the ability of non-respiring yeast (ρ°) yeast to grow by 30%, so that ρ° growth rates approach those of wild-type ρ+ yeast, see in particular strains PTY44 and BFY111. As also shown in Table 2, transgenic non-respiring yeast bearing mitochondrial genome lacking the COX3 gene showed a doubling time also approaching the doubling times of wild-type ρ+ yeast.
a and
Table 3 below provides comparative growth and ethanol production in batch fermentation of yeast bearing intact mitochondrial DNA (Rho+), yeast lacking mitochondrial DNA (Rho0), yeast lacking mitochondrial DNA but containing the ATP1-111 mutation (ATP1-111 Rho0), and yeast bearing a mitochondrial genome lacking the COX3 gene (Rho+Mit−).
As shown in Table 3 and previously shown in
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions, and sub-combinations as are within their true spirit and scope.
The foregoing discussion of the disclosure has been presented for purposes of illustration and description. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the disclosure are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed disclosure requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate preferred embodiment of the disclosure.
The use of the terms “a,” “an,” and “the,” and similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if the range 10-15 is disclosed, then 11, 12, 13, and 14 are also disclosed. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
The present application claims priority of U.S. Provisional Patent Application Ser. No. 61/808,116, filed on Apr. 3, 2013, entitled “ENHANCED YEAST FERMENTATION PLATFORM USING YEAST LACKING MITOCHONDRIAL DNA AND CONTAINING GROWTH IMPROVING MUTATIONS,” the entire contents are herein incorporated by reference for all it teaches and discloses.
This invention was made, in part, with government support awarded by the National Institutes of Health grant # GM068066. Accordingly, the United States government has certain rights in this invention.
Number | Date | Country | |
---|---|---|---|
61808116 | Apr 2013 | US |